Abbott says it will separate its global nutrition unit into an independent, publicly traded company, with about $8.5bn in annual sales. Multiple outlets report the move is linked to heightened attention around baby formula, as well as the company’s broader corporate restructuring plans.

The Financial Times frames the spin-off in the context of baby formula-related lawsuits, describing the nutrition unit as the focus of legal scrutiny. Quartz instead emphasizes the scale of the business and provides timing and guidance context, saying the separation is expected by the end of 2027 and that 2026 guidance remains unchanged.

Across coverage, outlets largely agree on the central elements: Abbott’s intention to create a standalone public company from its nutrition segment, and the approximate sales figure. Differences are mainly in what each outlet foregrounds—legal backdrop versus business scale and planning details—rather than in the core facts of the transaction.